News/Events
Subscribe to get latest news
News
Flamingo Therapeutics Announces Participation in Upcoming Investor and Industry Conferences
Flamingo Therapeutics (“Flamingo”) today announced its participation in the following upcoming investor and industry conferences:
Flamingo Therapeutics Appoints Leading Medical Oncologist Ezra Cohen, MD to its Board of Directors
Flamingo Therapeutics (“Flamingo”) today announced the appointment of Ezra Cohen, MD to its Board of Directors. Dr. Cohen is a leading medical oncologist and cancer researcher who brings unique and relevant expertise in the development of drugs, especially head and neck cancer, to the Flamingo board.
Flamingo Therapeutics Announces First Patient Dosed in Phase II PEMDA-HN Study for Head and Neck Squamous Cell Carcinoma (HNSCC)
Flamingo Therapeutics (“Flamingo”) today announced that the first patient has been dosed in its PEMDA-HN trial evaluating danvatirsen in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with recurrent/metastatic head and neck squamous cell
Flamingo Therapeutics Announces Poster Presentation at ESMO Congress 2023
Flamingo Therapeutics (“Flamingo”) today announced the presentation of a “Trials-in-Progress”, or TiP, poster at the ESMO Congress 2023, taking place October 20-24, 2023, in Madrid, Spain.
Flamingo Therapeutics Announces Participation at Upcoming Investor and Industry Conferences
Flamingo Therapeutics (“Flamingo”) today announced that company management will participate at several upcoming investor and industry conferences in October 2023:
Flamingo Therapeutics Receives €1.7M Grant Award from VLAIO to Advance RNA-Targeting Oncology Portfolio
Flamingo Therapeutics (“Flamingo”) today announced that it has been awarded a research grant of €1.7 million by Flanders Innovation & Entrepreneurship (VLAIO). The award represents the funding at 60% of a €2.9 million project.
Media
Can Cancer Be Treated by Changing Its Cells?
In 2017, Karen Kostroff, a renowned oncology surgeon at Northwell Health in the New York Metropolitan area added a new talking point ...
The dark matter of the genome: Flamingo Therapeutics taps potential of mysterious RNA for cancer therapies
Flamingo Therapeutics was born out of a collaboration between three partners in Flanders – VIB, UGent and KU Leuven – and the University of Michigan ...
Leuvense biotechstarter mikt op nieuwe kankertherapieën
Flamingo werd vorig jaar opgericht als spin-off van het Vlaams Instituut voor Biotechnologie (VIB), de KU Leuven en UGent, maar opereerde ...
Ionis collaborator Flamingo is ready to take flight with 3 antisense drugs in the clinic and mysterious RNA in its sights
As the biggest name in antisense technology, Ionis has long focused on testing the interplay between oligonucleotides and RNA for therapeutic effect ...